In July 2025, GP2 announced the 10th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 11,109 additional genotyped participants and 13,339 additional WGS participants. The genotype array (NBA) data, including locally-restricted samples, now consists of a total of 82,944 genotyped participants (36,939 PD cases, 19,821 Controls, and 26,184 ‘Other’ phenotypes). When removing the locally-restricted samples, these now consist of 65,303 samples (28,586 PD cases, 15,258 Controls, and 21,459 ‘Other’ phenotypes). The whole genome sequencing (WGS) data now consists of a total of 21,073 sequenced participants (8,134 PD cases, 3,531 Controls, and 9,408 ‘Other’ phenotypes). When removing the locally-restricted samples, these now consist of 16,608 participants (6,801 PD cases, 3,244 Controls, and 6,563 ‘Other’ phenotypes). Of note, cases recruited via the Monogenic network are coded as ‘Other’. The clinical exome data now consists of 10,454 samples with PD (Release 8). Of the 92,021 unique samples with genetic data (NBA, WGS, or clinical exome), 26,982 individuals also have additional extended clinical information. Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.15748014, release 10) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org."